Free Trial
NASDAQ:UPB

Upstream Bio Q2 2025 Earnings Report

Upstream Bio logo
$15.84 -0.88 (-5.26%)
Closing price 08/7/2025 04:00 PM Eastern
Extended Trading
$15.84 0.00 (-0.03%)
As of 08/7/2025 04:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Upstream Bio EPS Results

Actual EPS
-$0.74
Consensus EPS
-$0.61
Beat/Miss
Missed by -$0.13
One Year Ago EPS
N/A

Upstream Bio Revenue Results

Actual Revenue
$0.94 million
Expected Revenue
$0.32 million
Beat/Miss
Beat by +$623.00 thousand
YoY Revenue Growth
N/A

Upstream Bio Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Wednesday, August 6, 2025
Conference Call Time
4:00PM ET

Upstream Bio Earnings Headlines

Upstream Bio (UPB) Q2 R&D Soars 169%
Upstream Bio, Inc. reports Q2 results
GENIUS Act: Cancel Your Money?
A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. Backed by the government but powered by private corporations, this initiative paves the way for digital dollars—programmable, trackable, and outside your control. Once embedded into apps, banks, and retail systems, opting out may no longer be possible. But there’s still time to protect your financial freedom—if you act before the system goes fully live.
Upstream Bio (UPB) Expected to Announce Earnings on Tuesday
See More Upstream Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Upstream Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Upstream Bio and other key companies, straight to your email.

About Upstream Bio

Upstream Bio (NASDAQ:UPB), a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

View Upstream Bio Profile

More Earnings Resources from MarketBeat